Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with a primary product offering (lead drug) that is typically in a Phase 1, Phase 2 or Phase 3 clinical trial stage of development, but prior to receiving marketing approval.
Frequently asked questions
What is the Virtus LifeSci Biotech Clinical Trials ETF (BBC) expense ratio?
The Virtus LifeSci Biotech Clinical Trials ETF funds expense ratio is 0.79%.
What is Virtus LifeSci Biotech Clinical Trials ETF (BBC) current stock price?
As of the latest data, Virtus LifeSci Biotech Clinical Trials ETF stock price is $41.23, with a previous close of $40.84. Virtus LifeSci Biotech Clinical Trials ETF gained $0.39 in the last trading session, representing a 0.95% increase.
Does Virtus LifeSci Biotech Clinical Trials ETF (BBC) pay dividends?
Yes. Virtus LifeSci Biotech Clinical Trials ETF pays annual dividends with an annualized yield of 1.59% and an estimated annual payout of $0.66 per share.
